Cephalon will give Barr Pharmaceuticals a license to sell a generic version of the pain drug Fentora in 2018 as part of a patent lawsuit settlement, according to a regulatory filing. Cephalon (CEPH) said it will give Barr a nonexclusive, royalty-free right to sell a generic version of Fentora in October of 2018. Cephalon claimed Barr infringed Fentora patents that don't expire until 2019. Under the settlement, Barr, a unit of Teva Pharmaceutical